Research biopsies are frequently incorporated within clinical trials in oncology and are often a mandatory requirement for trial enrollment. However, limited information is available regarding the extent and completeness of research biopsy reporting.
T he need to characterize the tumor and its microenvironment has led to the increased use of research biopsies to obtain tumor tissue for correlative science. 1, 2 As the use of research biopsies becomes more entrenched, there is a critical need to ensure transparent reporting of results obtained from such biopsies. In clinical trial research, a procedure with individual patient risk is justifiable based on the expectation that generalizable knowledge will be gained. In a recent study by Parseghian et al, 3 a single-institution cohort demonstrated that 39%
of clinical trials that included research biopsies reported results from such biopsies. To determine the generalizability of these findings, this study evaluates research biopsy reporting in a large clinical trial database.
Methods

Identification of Trials
We searched ClinicalTrials.gov (CTG) for all oncologic investigational studies with completion dates from January 
Evaluation of Biopsy Reporting
Biopsy reporting was defined as either the mentioning of biopsies having been performed or the analysis of biopsycollected tumor tissue in any part of a published report or registry. The publication status for each trial in CTG was assessed by PubMed and Google Scholar searches using the investigators' names, part or all of the trial title, and various key words. If a publication was not identified, an evaluation for online reporting in CTG and pharmaceutical company registries was conducted. The date of the final publication search was March 12, 2018. Final reporting was defined by either a publication or CTG listing.
Statistical Analysis
The χ 2 and Fisher exact tests were used to investigate factors associated with biopsy reporting. Linear regression was used to assess the association between year of trial completion and the rate of mandatory biopsy and biopsy reporting. The Cochran-Armitage test for trend was used to identify the trend of mandatory biopsy inclusion over time. A 2-sided t test was used to assess for a difference between the slopes of inclusion of mandatory biopsies and biopsy reporting. A 2-sided P value <.05 was considered significant. The primary end point of this study was rate of clinical trial research biopsy reporting in a publication or registry. Secondary end points included the identification of factors associated with research biopsy reporting. Statistical analysis was conducted with SAS (version 9.4; SAS Institute).
Results
Clinical Trial Characteristics
Characteristics of the 301 clinical trials are listed in the Table. A median of 37 partients (range, 1-1310 patients) were enrolled per trial. Nearly half of all trials performed mandatory biopsies, 145 of 301 (48.2%), and the rate of inclusion of mandatory biopsies increased steadily over the years included in this analysis (P = .001) (Figure) . Only 86 of 301 trials (28.6%) conducted serial biopsies, and a research biopsy was listed as a primary objective in CTG in 72 of 301 trials (23.9%).
Factors Correlating With Research Biopsy Reporting and Publication
After a median follow-up of 5. Findings In this study, only 50.8% of trials that included a research biopsy-related end point reported on these biopsies. The percentage of conducted mandatory biopsies increased significantly over time, and these biopsies were also more likely to be reported in ClinicalTrials.gov and publications.
Meaning Improved efforts are needed by sponsors and investigators to report results obtained from research biopsies. (Figure) . The only factor that correlated with clinical trial reporting was phase 2 or 3 studies in comparison with phase 1 or 1/2 studies (72.3% [107 of 148] vs 89.5% [137 of 153]; P < .001) (Table) .
Discussion
This retrospective analysis of a large clinical trial registry suggests that only 153 of 301 (50.8%) of clinical trials report research biopsies. In addition, reporting was significantly less for clinical trials in which results were reported only in a registry ( Prior investigations have found that a high rate of clinical trials in oncology remain unpublished. [3] [4] [5] [6] [7] [8] Due to these findings, recent regulations have been enacted to require clinical trial result reporting. 9 However, these efforts are limited to outcome measures that are part of a clinical trial's statistical analysis plan, and thus are unlikely to include most research biopsies. 10 Our finding that only 11 of 49 (22.4%) of trials that conducted research biopsies reported on the conduct of these biopsies when listed in CTG supports this concern. One of the major findings of this study was the identification of factors that correlate with improved reporting of research biopsies. In particular, we found that the percentage of conducted mandatory biopsies increased significantly over time, and that these biopsies were also more likely to be reported in CTG and publications. Although all research biopsies should be reported for transparency, these data suggest that optional biopsies may be leading to insufficient evidence to answer a scientific question, and hence, are not being reported. Alternatively, researchers may feel more ethically inclined to report mandatory biopsies. In addition, the listing of a biopsy as a primary objective in CTG correlated with improved research biopsy reporting. Both of these findings reflect the integral incorporation of research biopsies into a clinical trial and provide guidance to investigators that scientifically rigorous integration of research biopsies into clinical trials may lead to improved final reporting.
Limitations
There are limitations to the study. Despite the large number of clinical trials evaluated, this work represents the findings from a single registry regarding the planned conduct of research biopsies. There is likely selection bias regarding the trials that reported results. We relied on trials that were indicated in CTG as being completed to ensure adequate time to publication (median, 5.8 years from trial completion to this analysis and ≥3 years in 100% of trials). Prior studies evaluating time from clinical trial completion until publication have reported a median time of 21 to 25 months (interquartile range, 13-37 months). 11, 12 The number of biopsies ultimately performed within each trial could not be determined.
Conclusions
In this era of molecular medicine, there has been an increased demand for fresh tumor tissue in clinical trials for purposes of proof-of-concept biomarker development, understanding of resistance mechanisms, and evaluating response. Using CTG-a large, public clinical trial database-our results suggest that many research biopsies are unreported. Increased efforts are needed to improve the reporting of research biopsies, not only as an ethical duty to patients, but also for the benefit of the scientific community.
